The UK Biobank Pharma Proteomics Project (UKB-PPP) aims to use Olink® Explore HT to measure over 5,400 proteins in 600,000 samples from UKB participants. The collaboration between the UKB and 14 leading biopharmaceutical companies represents the largest study of its kind ever undertaken and will create a comprehensive map of protein levels in the human body to advance our understanding of disease.

In the pilot phase of the UKB-PPP, Olink Explore 3072 was used to measure ~3,000 proteins in over 54,000 UKB participants. Following three landmark publications in Nature from consortium members in late 2023, this unique dataset was made available to the wider scientific community. Well over 100 peer-reviewed articles using the UKB-PPP dataset and citing the use of Olink data were published in 2024 alone, encompassing all major disease areas represented in the UK Biobank, illustrating the power of the project to deliver meaningful new discoveries relevant to future drug development and human healthcare.